Mutations in BRAF, a component of extracellular signalregulated kinases 1 and 2 (ERK) cascade, are frequent in melanoma. It is important to understand how BRAF mutations contribute to malignant traits including anchorage-and growth factor-independence. We have previously shown that efficient activation of ERK in normal human epidermal melanocytes (NHEM) requires both adhesion to the extracellular matrix and growth factors. Mutant V599E BRAF is sufficient to promote ERK activation independent of adhesion and growth factors. Here, we analysed regulation of G1 cell cycle events in NHEM and human melanoma cells. We show that S phase entry in NHEM requires both adhesion and growth factor signaling through the MEK-ERK pathway. This control correlates with induction of cyclin D1 and downregulation of p27 Kip1 , two key G1 cell cycle events. In melanoma cells expressing V599E BRAF, cyclin D1 was constitutively expressed independent of adhesion but dependent upon MEK activation and nuclear accumulation of ERK. Reduction of cyclin D1 levels by RNA interference inhibited S phase entry in melanoma cells. Importantly, expression of V599E BRAF in NHEM was sufficient to promote cyclin D1 promoter activity in the absence of adhesion. Additionally, p27
Introduction
Malignant melanoma is an aggressive cancer with a rapidly rising incidence rate (Sauter and Herlyn, 1998) . At present, early detection and surgical removal is the only effective method to prevent metastasis. If undetected at an early stage, melanoma is associated with a poor clinical prognosis. Cutaneous melanomas arise from epidermal melanocytes, the pigment-producing cells in the skin. Radial growth phase (RGP) of melanoma is associated with horizontal cell growth within the epidermis (in situ) and growth as nests slightly down into the papillary dermis layer (microinvasion). In the subsequent vertical growth phase (VGP), melanoma cells invade into and grow within the dermis. Movement of cells out of the dermis and their dissemination to secondary sites defines the metastatic phase (Chin, 2003) .
Adhesion to the extracellular matrix (ECM) plays an important role in the growth and migratory properties of normal and malignant cells. The main cellular ECM receptors are the integrins that bridge the ECM to the actin cytoskeleton via focal adhesion complexes (Hynes, 2002) . Integrin-mediated adhesion regulates many cellular processes including G1 phase cell cycle progression (Assoian, 1997) . The activities of G1 phase cyclindependent kinases (CDKs) are positively regulated by associations with cyclin proteins and negatively regulated by CDK inhibitor proteins (Sherr, 1996) . Studies mainly in fibroblasts and endothelial cells demonstrate that integrin-mediated adhesion cooperates with growth factor signaling to control the induction of cyclin D1 and suppression of the CDK inhibitors, p21
Cip1 and p27
Kip1 (Fang et al., 1996; Zhu et al., 1996; Bottazzi et al., 1999; Mettouchi et al., 2001) . In malignant cancer cells, deregulation of adhesion-dependent signals promotes anchorage-independent growth, a characteristic that correlates with tumorigenicity in vivo (Freedman and Shin, 1974; Schwartz, 1997) .
Currently, little is known about integrin-dependent signaling events in normal human epidermal melanocytes (NHEM). We recently demonstrated that basal extracellular signal regulated kinases 1 and 2 (ERK) activity is low and growth factor-induced ERK activation is dependent on integrin-mediated adhesion in primary human melanocytes (Conner et al., 2003) . In other cell types, growth factor signaling through the RAF-MEK-ERK pathway plays an important role in regulating the levels of G1 cell cycle proteins, such as cyclin D1 and p27
Kip1 (Albanese et al., 1995; Lavoie et al., 1996; Greulich and Erikson, 1998) . However, additional pathways are also involved. The rac, PI-3 kinase/AKT, and integrin-linked kinase signaling pathways influence cyclin D1 and/or p27 Kip1 levels via mechanisms that are independent of MEK-ERK signaling (Gille and Downward, 1999; D'Amico et al., 2000; Mettouchi et al., 2001; Fujita et al., 2002; Shin et al., 2002) . Thus, while integrin control of the ERK cascade provides a possible mechanistic basis for adhesion-dependent proliferation, how it regulates G1 cell cycle events in NHEM remains to be determined.
We and others recently showed that metastatic melanoma cells display high basal ERK activity that is adhesion-independent (Conner et al., 2003; Satyamoorthy et al., 2003) . Two-thirds of cutaneous melanomas are associated with mutations in BRAF, one of three RAF kinases that act as activators of MEK1/2 in the ERK cascade (Davies et al., 2002) . The most common mutation in BRAF results in a V599E phospho-mimetic substitution (may also be referred to as V600E; Kumar et al., 2003) within the activation loop that enhances BRAF activity (Davies et al., 2002) . Furthermore, in both adherent and nonadherent melanoma cells, active ERK accumulates in the nucleus and influences transcriptional events (Conner et al., 2003) . Downregulation of mutant BRAF levels or inhibition of MEK abrogates anchorage-independent growth of melanoma cell lines (Collisson et al., 2003; Hingorani et al., 2003; Karasarides et al., 2004; Sumimoto et al., 2004) . Thus, the ability of melanoma cells to subvert adhesion control of MAPK/ERK kinase (ERK) signaling to the nucleus is likely to contribute to their anchorage independence. However, since BRAF mutations are also found in melanocytes within benign nevi (Dong et al., 2003; Pollock et al., 2003) , the mechanisms whereby mutant BRAF contributes to melanocytic transformation remains unclear. Previous reports have shown that expression of mutant BRAF leads to transformation of immortalized mouse cell lines (Govindarajan et al., 2003; Wellbrock et al., 2004) , but its effects in primary human melanocytes are poorly studied.
Here, we focus on the role of adhesion and MEK-ERK signaling in the control of cyclin D1 and p27 Kip1 expression in NHEM and human melanoma cells. We demonstrate that S phase entry and levels of cyclin D1 and p27
Kip1 are dependent on the MEK-ERK pathway in NHEM. Furthermore, adhesion to fibronectin also regulates levels of cyclin D1 and p27
Kip1
. In VGP and metastatic melanoma cells that harbor V599E BRAF mutations, the MEK-ERK pathway signals to constitutively express cyclin D1 independent of adhesion and to downregulate p27 Kip1 . Expression of active forms of BRAF in NHEM is sufficient to promote cyclin D1 promoter activity and downregulate p27
Kip1 in an adhesion-independent manner. Together, these findings indicate that adhesion and growth signals cooperate via ERK to regulate cyclin D1 and p27
Kip1 in NHEM, but adhesion control of these G1 cell cycle proteins is deregulated by mutation of BRAF in melanoma cells.
Results

Entry into S phase in human melanocytes is MEK-ERK-dependent
We recently showed that activation of ERK1/2 in NHEM is jointly controlled by adhesion to fibronectin and growth factors. Since the MEK-ERK pathway controls proliferation in many cell types, we analysed its requirement for entry into S phase in NHEM. Serumstarved cells were attached to fibronectin for 1.5 h, stimulated with basic FGF, TPA, and insulin. In some cultures, MEK activity was blocked with the pharmacological inhibitor, U0126. Growth factor-stimulated melanocytes efficiently incorporated BrdU indicating entry into S phase after 36 h, whereas cells treated with U0126 showed dramatically less BrdU incorporation ( Figure 1a) .
We next determined the G1 cell cycle components that are regulated via MEK-ERK signaling in NHEM. Growth factor-mediated induction of cyclin D1 was blocked by treatment with U0126, but was unaltered by treatment with 5 mM LY294002, an inhibitor of PI-3 kinase (Figure 1b) . The same treatment with LY294002 decreased levels of phospho Akt and treatment with a higher concentration (20 mM) still did not inhibit cyclin D1 expression (data not shown). High levels of the CDK inhibitor, p27 Kip1 , were expressed in adherent serumstarved NHEM and were downregulated after stimulation with growth factors (Figure 1c) . Notably, in the presence of U0126, growth factor-mediated downregulation of p27
Kip1 was blocked. However, treatment with LY294002 had no effect on p27 Kip1 downregulation. These findings are consistent with a role for the MEK-ERK pathway in regulating S phase entry in human melanocytes via cyclin D1 and p27
Kip1
.
Growth factor-induced cyclin D1 induction, p27 Kip1 downregulation, and entry into S phase require adhesion to the ECM To determine the role of adhesion to the ECM in controlling levels of cyclin D1 and p27
Kip1 in NHEM, cells were replated onto either fibronectin to which they adhere via the integrin a5b1 (Hara et al., 1994) or polylysine, a condition when integrins are not engaged. NHEM replated onto fibronectin displayed a polarized morphology, whereas on poly-lysine they attached but remained round and failed to extend processes (Supplementary Figure 1 ). In bromodeoxyuridine (BrdU) incorporation experiments in the presence of growth factors, NHEM entered S phase efficiently on fibronectin but inefficiently on poly-lysine (Figure 2a) . NHEM plated onto poly-lysine in the presence of growth factors did not display significant levels of apoptosis, as determined by TdT-mediated dUTP Nick-End Labeling (TUNEL) (K Adamo and AE Aplin, data not shown). Cells replated in the absence of growth factors either on fibronectin or poly-lysine failed to enter S phase ( Figure 2a) .
We next analysed the role of adhesion in the expression of cyclin D1 and p27
. As observed by Western blot analysis, serum-starved NHEM displayed barely detectable levels of cyclin D1 when replated onto either fibronectin or poly-lysine in the absence of growth factors (Figure 2b ). Cyclin D1 was robustly expressed in cells on fibronectin in the presence of growth factors over a 24 h time period. However, the levels of cyclin D1 were low in growth factor stimulated cells attached to poly-lysine. CDK2 levels were similar on fibronectin and on poly-lysine. Quantitation of Western blot analysis from three independent experiments showed that the induction of cyclin D1 was three-fold higher in melanocytes adhered to fibronectin compared to those on poly-lysine (Figure 2c ). High levels of p27
Kip1 in serum-starved NHEM were efficiently downregulated upon growth factor stimulation in cells adherent to fibronectin. In contrast, growth factor-mediated downregulation of p27
Kip1 was inefficient in NHEM on polylysine (Figures 2d and e) .
In summary, efficient cell cycle progression in NHEM requires the cooperation between adhesion and growth factor signals. Our results demonstrate that this cooperation controls the efficient cyclin D1 induction and down-regulation of p27 Kip1 , two key G1 cell cycle proteins, in a MEK-ERK-dependent manner.
Cyclin D1 expression is MEK-dependent but adhesion-independent in melanoma cells
In many melanoma cell lines, ERK1/2 is constitutively active and accumulates in the nucleus under basal conditions due to mutation of BRAF; hence, we analysed the role of adhesion and MEK-ERK signaling in cyclin D1 expression in melanoma cells. We focused on two melanoma cell lines: SK-MEL-28 and WM793 derived from the metastatic and VGP phases, respectively. Both SK-MEL-28 and WM793 cells are known to harbor V599E BRAF mutations (Davies et al., 2002; Satyamoorthy et al., 2003) and express high levels of cyclin D1 compared to NHEM (Figure 3a) .
SK-MEL-28 and WM793 cells were replated onto either fibronectin or poly-lysine in serum-free medium. Both cells lines attached to poly-lysine but failed to spread properly within 12 h, although partial spreading was observed by 24 h. Elevated expression of cyclin D1 was maintained in SK-MEL-28 cells replated in serumfree conditions on poly-lysine or maintained in suspension (Figures 3b and c) . Treatment with U0126 dramatically reduced expression of cyclin D1 in both adherent and nonadherent cells. Typically, levels of cyclin D1 were reduced within 3 h of treatment with U0126 and barely detectable after 6 h ( Supplementary  Figures 2a and b ). ERK1/2 levels were comparable between adherent and nonadherent conditions. In some experiments, a mobility shift indicative of activated ERK was observed.
Cyclin D1 was also highly expressed in WM793 cells replated onto poly-lysine ( Figure 3d ). Similar results were obtained when cells were kept in suspension or cultured on agar-coated dishes (data not shown), indicating that expression was independent of cell attachment and spreading. Treatment with U0126 blocked cyclin D1 induction under all replating conditions ( Figure 3d ). Quantification of Western blots showed that cyclin D1 levels decreased by 95 and 84% in SK-MEL-28 and WM793 cells, respectively, after 24 h of MEK inhibition (Supplementary Figure 2) . These (c) Levels of immunoreactivity were quantified using a Fluor-S Multi-Imager and Quantity One software. Shown are the mean and standard deviation of the cyclin D1 to CDK2 ratios relative to unstimulated cells on poly-lysine from three independent experiments. Using the Student's t-test (two-tailed), the increase in cyclin D1 levels on fibronectin at 24 h compared to poly-lysine at 24 h is statistically significant (*Po0.01). (d) NHEM cell lysates were analysed by Western blotting with antibodies to p27 Kip1 (upper panel) and, as a loading control, CDK2 (lower panel). (e) Shown are the mean and standard deviation from three independent experiments for levels of p27
Kip1 to CDK2 relative to unstimulated cells on poly-lysine. Using the Student's t-test (two-tailed), the decrease in p27
Kip1 levels on Fn/GF at 24 h compared to P-Lys/GF at 24 h is statistically significant (*Po0.02)
Signaling in human melanocytes and melanoma cells KV Bhatt et al data show that cyclin D1 levels are adhesion-independent in melanoma cells that harbor V599E BRAF mutations.
Cyclin D1 expression in melanoma cells requires nuclear accumulation of ERK
To analyse the effect of blocking ERK nuclear accumulation, we transfected SK-MEL-28 cells with a construct encoding a substrate-trapping version of MKP3 (MKP3 C/S). MKP3 is a cytoplasmic phosphatase that specifically dephosphorylates active ERK. MKP3 C/S is known to block nuclear accumulation of ERK by retaining ERK in the cytoplasm but does not block phosphorylation of a membrane-localized form of Elk-1 or activation of cytoplasmic p90 Rsk1 (Brunet et al., 1999) . SK-MEL-28 cells expressing MKP3 C/S, as detected by Myc staining, showed a loss of nuclear cyclin D1 staining compared to non-transfected cells (Figure 4 , upper panels). Consistent with previous reports (Brunet et al., 1999; Lai et al., 2002) , expression of MKP3 C/S led to a loss of nuclear ERK (Figure 4 , lower panels). These results indicate that cyclin D1 levels are dependent on nuclear accumulation of ERK in human SK-MEL-28 melanoma cells.
Reduction of cyclin D1 expression inhibits melanoma cell entry into S phase
To determine whether the enhanced expression of cyclin D1 regulates entry into S phase in melanoma cells, we utilized RNA interference to reduce cyclin D1 levels. WM793 cells were transfected with cyclin D1 siRNA or control siRNA for 72 h and the levels of cyclin D1 were analysed by Western blotting. Cyclin D1 protein levels were efficiently reduced in cells transfected with cyclin D1 siRNA ( Figures 5a and b) ; however, the levels of cyclin D3 and tubulin remained unaltered. Notably, hyperphosphorylation of retinoblastoma and expression of cyclin A, markers of G1 cell cycle progression and entry into S phase (Pagano et al., 1992) , were efficiently decreased in cyclin D1 knockdown cells compared to controls (Figures 5a and b) .
To directly measure entry into S phase, we added BrdU to the medium of cyclin D1 and control knockdown cells for 8 h and measured BrdU incorporation by immunofluorescence. On average 17.5% of cyclin D1 knockdown cells incorporated BrdU compared to 51.5% of controls (Figure 5c ). Finally by directly counting cells, we observed a 66% decrease in cell numbers in the cyclin D1 knockdown transfection compared to controls after 72 h. Together, these data show that the enhanced cyclin D1 expression in melanoma cells contributes to G1 to S phase progression and proliferation.
Expression of V599E BRAF is sufficient to promote adhesion-independent cyclin D1 promoter activity in NHEM To test the role of mutant BRAF in cyclin D1 induction, we first determined whether V599E BRAF was sufficient to induce cyclin D1 expression. We expressed mutant V599E and wild-type forms of BRAF in adherent NHEM in the absence of growth factors. Coimmunofluoresence staining was performed for the myc epitope tag on BRAF and cyclin D1. Expression of V599E BRAF was sufficient to induce expression of cyclin D1 in the majority (81%) of myc-staining cells (Figure 6a ). In comparison, expression of wild-type BRAF was insufficient to induce high levels of cyclin D1 expression. We next utilized a construct encoding the À964 promoter region of cyclin D1 controlling expression of firefly luciferase, a frequently used cyclin D1 reporter that is activated by ERK signaling in several cell types (Albanese et al., 1995; Wantanabe et al., 1996) . Luciferase levels were low in vector control transfected cells (Figure 6b ). Coexpression of V599E BRAF enhanced cyclin D1 promoter activity, as indicated by increased luciferase expression, an effect that was reduced upon treatment with U0126.
We determined whether V599E BRAF was sufficient to promote cyclin D1 promoter activity in the absence of integrin-mediated adhesion. To this end, NHEM were transfected with a À964 cyclin D1 luciferase reporter and either V599E BRAF or vector control and replated onto fibronectin or poly-lysine in serum-free medium. Cyclin D1-luciferase activity was low in control-transfected cells on either poly-lysine or fibronectin after 20 h (Figure 6c) . Notably, V599E BRAF efficiently promoted luciferase levels in both cells adherent to fibronectin and attached to poly-lysine. Hence, V599E mutation of BRAF enhances cyclin D1 promoter activity via MEK-ERK, but independent of adhesion and growth factors in NHEM.
P 27kip1 expression is downregulated via BRAF-MEK-ERK signaling in NHEM and melanoma cells
We next investigated whether the MEK-ERK pathway regulated p27
Kip1 levels in V599E BRAF-harboring melanoma cells, SK-MEL-28 and SK-MEL-24. Levels of p27
Kip1 were low in serum-starved cultures of SK-MEL-28 and SK-MEL-24 cells and treatment with the MEK inhibitor, U0126, led to an increase in p27
Kip1
( Figure 7a ). Similar results were observed in WM793 cells (not shown).
To determine whether V599E BRAF was sufficient to downregulate p27
Kip1 in NHEM, we expressed V599E BRAF in these cells and analysed p27
Kip1 levels by immunofluorescence. Serum-starved adherent NHEM clearly expressed high levels of p27 Kip1 in the nucleus; however, in V599E BRAF expressing cells p27
Kip1 levels were barely detectable (Figure 7b) (Figure 7c ). Together, these data indicate that activated BRAF is sufficient to downregulate p27 Kip1 levels.
Discussion
Our studies provide mechanistic details underlying adhesion-dependent cell cycle events in normal cells and how mutations associated with malignant transformation overcome adhesion control. Previously, we have shown that adhesion and growth factors cooperate to control efficient activation of ERK in primary human melanocytes (Conner et al., 2003) . Furthermore, mutations in BRAF, which are associated with approximately 70% of melanomas, lead to adhesion and growth factorindependent activation of ERK in human melanoma cells (Conner et al., 2003) . In this study, we report downstream effects on cyclin D1 and p27
Kip1
, two G1 cell cycle components that are frequently altered in human tumors (Figure 8 ).
In NHEM, we find that cyclin D1 induction and p27
Kip1 downregulation are dependent on adhesion to fibronectin and growth factors, an effect that correlates with adhesion-dependent S phase entry. While it is known that fibronectin is able to regulate melanocyte morphology and proliferation (Hedley et al., 1997; Takano et al., 2002) , here we show integrin-mediated adhesion and growth factors cooperate to control S phase entry. Neither adhesion to the ECM nor growth factor stimulation alone is sufficient. These results in NHEM are similar to findings in fibroblasts, the most widely used cell type for adhesion studies (Zhu et al., 1996; Danen et al., 2000) . Melanocytes normally reside at the epidermal-dermal border along the cutaneous basement membrane. In this environment, melanocytes are not highly proliferative. Melanocyte interactions with fibronectin are associated with situations that require a high rate of proliferation. For example, during wound healing the cutaneous basement membrane is broken down and epidermal melanocytes and keratinocytes are stimulated to fill the wound bed consisting of a fibronectin-rich provisional matrix (Grinnell, 1992) . Additionally, fibronectin may be important for melanoblast proliferation and migration during development (Scott et al., 1992) . How integrin and growth factor signaling cooperate to control entry into S phase remains unclear. Cyclin D1 and p27
Kip1 levels are influenced by multiple signaling pathways including the MEK-ERK, integrin-linked kinase, Rho and PI-3 kinase/AKT cascades (for reviews see Pruitt and Der, 2001; Coqueret, 2002) . Also, recent findings demonstrate that the balance between Rac/Cdc42 and Rho activities controls the timing of cyclin D1 expression (Welsh et al., 2001) . We find that the MEK-ERK pathway controls both cyclin D1 and p27
Kip1 levels in NHEM. Notably, treatment with a PI-3 kinase inhibitor neither decreased cyclin D1 levels nor blocked p27 Kip1 downregulation. This contrasts with observations in fibroblasts and breast cancer cells in which PI-3 kinase-AKT signaling controls levels of these G1 proteins (Muise-Helmericks et al., 1998; Gille and Downward, 1999; Treinies et al., 1999; Busse et al., 2000; Collado et al., 2000) . Together, our findings indicate that integrin-growth factor cooperation in NHEM controls cyclin D1 and p27
Kip1 expression via the MEK-ERK pathway.
Cyclin D1 is frequently overexpressed in human tumors either due to gene amplification of the chromosomal region 11q13 or through upregulation of signaling pathways that control its expression (Bartkova et al., 1995; Sauter et al., 2002) . In contrast to normal melanocytes, cyclin D1 is highly expressed in melanomas in the absence of integrin-mediated adhesion and exogenous growth factors. Our data indicate that V599E mutant BRAF signals via MEK to by-pass the adhesion and growth factor requirements for cyclin D1 induction. Previously, divergent effects on cyclin D1 have been reported upon activating ERK in nonadherent fibroblasts (Le Gall et al., 1998; Roovers et al., 1999) . In one report, activation of ERK was sufficient to up-regulate cyclin D1 mRNA levels in suspended cells (Roovers et al., 1999) ; whereas in another study ERK activity was insufficient (Le Gall et al., 1998) . The importance of deregulation of cyclin D1 in melanoma is underscored V599E BRAF Figure 8 Model figure for adhesion-growth factor cooperation in NHEM and BRAF signaling in melanoma. In NHEM, adhesion to the ECM regulates growth factor signaling through the MEK-ERK pathway that controls the induction of cyclin D1 and downregulation of p27 Kip1 . In this manner, adhesion control of the ERK pathway regulates G1 cell cycle progression and entry into S phase. Mutations in BRAF are found in 70% of melanomas. Mutant BRAF is sufficient to activate ERK independent of adhesion, which in turn induces cyclin D1 and downregulates p27
Kip1 independent of adhesion and growth factors by our RNA interference data demonstrating that cyclin D1 contributes to entry into S phase. Additionally, previous studies show that antisense-mediated downregulation of cyclin D1 expression in melanoma cell lines reduces their tumorigenicity in vivo (Sauter et al., 2002) . The CDK inhibitor protein p27 Kip1 is frequently downregulated in human tumors via post-translational modifications that regulate its localization and degradation (Viglietto et al., 2002) . Our findings that mutant and active forms of BRAF are sufficient to downregulate p27
Kip1 in NHEM explains why p27 Kip1 levels are low in SK-MEL-28 and SK-MEL-24 cells and many other cutaneous melanoma cell lines (Kortylewski et al., 2001) . In contrast, expression of active Raf in human small lung cancer cell lines promotes upregulation of p27
Kip1 (Ravi et al., 1998) , although the reason for this difference is not known. The mechanism by which BRAF signaling through ERK regulates p27
Kip1 in NHEM and cutaneous melanoma cells is unclear. Delmas et al. (2003) show that ERK may regulate calpains to degrade p27
Kip1 in choroidal melanoma cells. Others have proposed that ERK may directly phosphorylate p27
Kip1 (Kawada et al., 1997) . An additional possibility is a mechanism involving Skp-2, an F-box protein that regulates ubiquitin-dependent degradation of p27
. Skp-2 levels are regulated by adhesion by both transcriptional and post-transcriptional mechanisms in fibroblasts (Carrano and Pagano, 2001) . Clearly, the mechanism(s) by which p27
Kip1 levels are controlled by adhesion and growth factors in NHEM and by mutant BRAF in melanoma cells warrants further examination.
Our findings provide important insights into the contribution of mutant BRAF to human melanocyte transformation. It was recently shown that expression of mutant BRAF or active MEK in immortalized mouse melanocyte cells promotes anchorage-independence (Govindarajan et al., 2003; Wellbrock et al., 2004) . Our studies in NHEM are particularly pertinent since BRAF mutations are commonly found in nevi, benign clusters of melanocytes and thus are unlikely to be sufficient to transform primary human melanocytes (Dong et al., 2003; Pollock et al., 2003) . This notion is consistent with findings that constitutive ERK activity often leads to cell cycle arrest in untransformed cells, an effect that is mediated by upregulation of CDK inhibitors, p21
Cip1 and/or p16 INK4a (Pumiglia and Decker, 1997; Zhu et al., 1998; Malumbres et al., 2000) . Notably, loss of expression/inactivation of either p16
INK4a or p21
Cip1 is linked to melanoma (Jiang et al., 1995; Cannon-Albright et al., 1996) . Future experiments will analyse whether adhesion and/or BRAF regulates the levels of these CDK inhibitors in NHEM.
In summary, we provide evidence that mutation of BRAF subverts adhesion control of the ERK1/2 pathway in melanoma cells leading to deregulation of cyclin D1 and p27
Kip1 levels, two key G1 cell cycle events. Understanding how mutations in BRAF alter the requirement for adhesion in processes such as proliferation, survival, and migration will shed light on how these frequent genetic alterations contribute to melanoma initiation and/or progression.
Materials and methods
Isolation and culture of primary NHEM
Neonatal foreskins were obtained according to Albany Medical College Institutional Review Board procedures. NHEM were isolated as previously described (Conner et al., 2003) . Briefly, foreskin tissue was incubated with dispase (1 mg/ml) for 24 h to separate the epidermis from the dermis. Separated epidermal sheets were incubated with trypsin for 20 min at 371C, vortexed, and the cells pelleted by centrifugation. Cells were cultured in MCDB 153 medium (Sigma) containing 0.2% (w/v) sodium bicarbonate (Cellgro), 0.5% (v/ v) fetal bovine serum (Hyclone), 0.05% (v/v) bovine pituitary extract (Invitrogen), 0.5 mg/ml hydrocortisone (Sigma), 10 mg/ ml insulin (Sigma), 1 ng/ml basic FGF (BD Biosciences), and 8 nM TPA (Calbiochem). NHEM from between passages 3 and 10 were used for experiments.
Expression of cDNA constructs in NHEM
Plasmids expressing wild-type and mutant BRAF were kindly donated by Dr Richard Marais, Institute of Cancer Research, London (Davies et al., 2002) . Plasmids were expressed in melanocytes either by transient transfection using Trans-It reagent (Mirus) or by electroporation using a Nucleofector (Amaxa Inc.).
Recombinant adenoviral infections
The delta BRAF-ER* cDNA in pBabepuro3 was a generous gift from Dr Martin McMahon (Cancer Research Institute and Department of Cellular and Molecular Pharmacology, UCSF). Delta BRAF-ER* expresses a N-terminally truncated active form of BRAF fused to a modified (G525R) estrogen receptor hormone domain (McMahon, 2001 ). The delta BRAF-ER* sequence was subcloned into pAdTrack vector and recombinant adenovirus was generated, as previously described (McMullen et al., 2004) . NHEM were infected with either pAdTrack that encodes GFP or pAdTrack delta BRAF-ER* for 12 h. Tamoxifen (Sigma) was added to the media to give a final concentration of 500 nM. Infected NHEM were then used in adhesion experiments.
RNA interference
Melanoma cells were transfected for 4 h with 25 nM chemically synthesized siRNA (Dharmacon) using OligofectAMINE (Invitrogen). Cells were harvested after a further 68 h. A non-silencing siRNA (purchased from Dharmacon) was used as a control.
Melanoma cell culture
Human SK-MEL-28 and SK-MEL-24 cells were purchased from ATCC and grown in Eagle's minimal essential medium (MEM) containing Earle's salts, 2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM. nonessential amino acids (all from Cellgro), 1.5% (w/v) sodium bicarbonate, and 10% fetal bovine serum. WM793 cells were kindly donated by Dr Meenhard Herlyn (Wistar Institute, Philadelphia) and were cultured in MCDB 153 containing 20% Leibovitz L-15 medium, 2% FBS, and 5 mg/ml insulin. SK-MEL-28 cells were transfected with a construct encoding a substrate-trapping mutant of MKP3 (Myc-MKP3 C/S) using LipofectAMINE Plus (Invitrogen) according to the manufacturer's guidelines. pSG5-Myc-MKP3 C/S was kindly provided by Dr S Keyse (Cancer Research UK, Dundee) (Groom et al., 1996) .
Cell adhesion
Cell cultures were serum-starved overnight. On the next day, cells were detached with trypsin and pelleted in MCDB 153 medium (NHEM/WM793 cells) or MEM (SK-MEL-28) containing 0.5% (w/v) BSA (Sigma) and 1 mg/ml soybean trypsin inhibitor (Gibco BRL). Cells were washed once and then replated onto either fibronectin (20 mg/ml; BD Biosciences) or poly-lysine (10 mg/ml; Sigma) in the appropriate medium containing 0.5% BSA at 371C. For NHEM experiments, cells were stimulated with 5 mg/ml insulin, 1 ng/ml basic FGF, and 8 nM TPA. In some experiments, the MEK inhibitor, U0126, and the PI 3-kinase inhibitor, LY294002 (both from Cell Signaling Technology) were utilized at concentrations of 10 and 5 mM, respectively. For these inhibitor studies, DMSO was used as a vehicle control.
Immunofluorescence staining
NHEM were plated onto fibronectin or poly-lysine-coated coverslips, as outlined above. For analysis of S phase entry, bromodeoxyuridine (BrdU) was added to the medium at a final concentration of 100 mM. At 36 h after replating, cells were washed with PBS and then fixed with 3.7% formaldehyde for 10 min at room temperature. Cells were further washed and permeablized for 5 min in PBS containing 0.5% Triton X-100. Slides were then treated with 0.1 units/ml DNAse for 30 min at 371C. BrdU incorporation was analysed with a sheep anti-BrdU antibody and rabbit anti-sheep IgG conjugated to FITC (Biodesign). Nuclei were stained with Hoechst reagent 33342 (Molecular Probes) at 1 mM/ml for 10 min at room temperature.
In transfection and electroporation experiments, cells were replated onto coverslips, fixed, and processed for doublelabeling immunofluorescence. Myc-MKP3C/S transfected SK-MEL-28 cells were doubly stained with monoclonal Myc-tag antibody (9B11; Cell Signaling Technology) and polyclonal antibodies for either ERK (C16; Santa Cruz Biotechnology) or cyclin D1 (M-20; Santa Cruz Biotechnology). For cyclin D1 analysis, NHEM-expressing exogenous BRAF were costained as above. For p27 Kip1 analysis, NHEM were stained with rabbit polyclonal BRAF (Santa Cruz, C-19) and mouse monoclonal p27 Kip1 (BD Biosciences, clone 57) antibodies. Coverslips were subsequently incubated with appropriate Alexa Fluor 594 and 488 secondary (Molecular Probes) antibodies.
Fluorescent staining was viewed on an Olympus BX60 microscope equipped for epifluorescence. Images were captured using a Spot CCD camera and processed using deconvolution Slide Book software.
SDS-PAGE and Western blotting
Cell lysates were separated by SDS-PAGE under reducing conditions and proteins were transferred electrophoretically onto Immobilon P membranes (Millipore Corp.) . Membranes were blocked with PBS containing 1% BSA and 0.1% Tween 20 for 1 h and subsequently incubated overnight with primary antibody at 41C. Primary antibodies that recognize phospho-ERK (Cell Signaling Technology), total ERK1/2 (K-23, Santa Cruz Biotechnology), cyclin D1 (DCS-6, BD Biosciences), CDK2 (M2, Santa Cruz Biotechnology), BRAF (C-19, Santa Cruz Biotechnology), p27
Kip1 (BD Biosciences, clone 57), cyclin D3 (DCS-22, NeoMarkers), phospho(780) Rb (Cell Signaling Technology), cyclin A (H-432, Santa Cruz Biotechnology), and b-tubulin (clone KMX-1, Chemicon) were used. Membranes were washed in PBS containing 0.1% Tween, and incubated with secondary antibodies conjugated to horseradish peroxidase (Calbiochem) for 1 h at room temperature. Western blots were developed using SuperSignal chemiluminescent substrate (Pierce). Immunoreactivity was detected and quantified using a Fluor-S MultiImager and Quantity-One software (BioRad).
Luciferase-based reporter assays
For cyclin D1 promoter assays, NHEM were transfected with a plasmid encoding the À964 region of the cyclin D1 promoter (Wantanabe et al., 1996) and pEFm-BRAF V599E or a vector control. pRL-TK-luc (Promega) that encodes the thymidine kinase promoter controlling Renilla luciferase was cotransfected for normalization. After a transfection period lasting 4 h, cells were replated onto fibronectin or poly-lysine, if indicated. Luciferase levels were determined using the dual luciferase assay kit (Promega). Firefly and Renilla luciferase activities were measured sequentially from the same sample using a Turner Designs 20/20 luminometer. For each sample, firefly luciferase activity was normalized to Renilla luciferase activity.
Abbreviations CDK, cyclin-dependent kinase; ECM, extracellular matrix; ERK, extracellular signal-regulated kinases 1 and 2; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; NHEM, normal human epidermal melanocytes; RGP, radial growth phase; TPA, 12-O-tetradecanoyl phorbol 13-acetate; VGP, vertical growth phase.
